497 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Acquired by Regent Peak Wealth Advisors LLC

Regent Peak Wealth Advisors LLC bought a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 497 shares of the pharmaceutical company’s stock, valued at approximately $202,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. OPTIMAS CAPITAL Ltd bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at $1,717,000. Princeton Global Asset Management LLC boosted its stake in shares of Vertex Pharmaceuticals by 1.7% in the 4th quarter. Princeton Global Asset Management LLC now owns 15,050 shares of the pharmaceutical company’s stock valued at $6,124,000 after purchasing an additional 255 shares during the last quarter. Drive Wealth Management LLC boosted its stake in shares of Vertex Pharmaceuticals by 4.9% in the 4th quarter. Drive Wealth Management LLC now owns 1,071 shares of the pharmaceutical company’s stock valued at $436,000 after purchasing an additional 50 shares during the last quarter. Pinnacle Financial Partners Inc bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at $261,000. Finally, Sigma Investment Counselors Inc. boosted its stake in shares of Vertex Pharmaceuticals by 440.0% in the 4th quarter. Sigma Investment Counselors Inc. now owns 7,252 shares of the pharmaceutical company’s stock valued at $2,951,000 after purchasing an additional 5,909 shares during the last quarter. 90.96% of the stock is owned by institutional investors.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 354 shares of Vertex Pharmaceuticals stock in a transaction on Monday, February 26th. The stock was sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the sale, the executive vice president now directly owns 55,804 shares in the company, valued at $23,755,762.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, EVP Ourania Tatsis sold 354 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the sale, the executive vice president now directly owns 55,804 shares in the company, valued at $23,755,762.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Kristen Ambrose sold 1,374 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $577,409.76. Following the completion of the sale, the chief accounting officer now owns 9,676 shares of the company’s stock, valued at $4,066,242.24. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 19,029 shares of company stock worth $7,989,227. 0.40% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Price Performance

VRTX opened at $409.42 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99. The stock has a market capitalization of $105.76 billion, a P/E ratio of 29.48, a P/E/G ratio of 2.29 and a beta of 0.35. The company’s 50-day simple moving average is $421.74 and its two-hundred day simple moving average is $392.87. Vertex Pharmaceuticals Incorporated has a 52-week low of $313.47 and a 52-week high of $448.40.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last announced its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.85 by $0.35. The business had revenue of $2.52 billion during the quarter, compared to analyst estimates of $2.50 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. During the same period last year, the firm posted $3.33 EPS. As a group, analysts predict that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Evercore ISI downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to an “in-line” rating and upped their price objective for the stock from $436.00 to $438.00 in a report on Tuesday, February 6th. Wolfe Research initiated coverage on shares of Vertex Pharmaceuticals in a report on Thursday, February 15th. They set an “outperform” rating and a $515.00 price objective on the stock. Robert W. Baird downgraded shares of Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 target price for the company. in a report on Wednesday, January 31st. Canaccord Genuity Group reiterated a “sell” rating and issued a $379.00 target price (up previously from $332.00) on shares of Vertex Pharmaceuticals in a report on Wednesday, January 24th. Finally, Canaccord Genuity Group downgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “sell” rating and increased their target price for the company from $332.00 to $379.00 in a report on Wednesday, January 24th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $420.48.

Check Out Our Latest Research Report on Vertex Pharmaceuticals

Vertex Pharmaceuticals Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Read More

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.